GH
Guardant Health, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$156.99
−2.51%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−52.8x
Market Cap
$21.07B
MomentumView details →
1D Return
−2.51%
YTD Return
+56.55%
RSI (14)
48.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−52.8x
Market Cap
$21.07B
RSI (14)
48.8
MomentumView details →
1D Return
−2.51%
YTD Return
+56.55%
SummaryUpdated Jun 1, 2026
Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company founded in 2011 and headquartered in Redwood City, California. The company went public in October 2018 and has established itself as a leader in liquid biopsy technology, which uses blood tests to detect and analyze cancer-related genetic material. Guardant Health operates primarily in the United States with expanding international presence, serving oncologists, patients, and biopharmaceutical companies with innovative blood-based cancer testing solutions.
Similar companies
Latest newsMore news →
Callan Family Office LLC acquired a new stake in Guardant Health, Inc. by purchasing 6,080 shares valued at approximately $912,000 in the second quarter, as disclosed in its 13F filing.10d agoOn August 24, 2026, Guardant Health Inc's shares fell 4.4% to $163.18.11d agoGuardant Health announced planned product launches in its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference.21d ago